UBS Group AG Cuts Stock Holdings in Inspire Medical Systems, Inc. $INSP

UBS Group AG reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 12.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 411,329 shares of the company’s stock after selling 56,407 shares during the quarter. UBS Group AG’s holdings in Inspire Medical Systems were worth $37,937,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Sanctuary Advisors LLC purchased a new position in Inspire Medical Systems during the fourth quarter worth about $481,000. Concurrent Investment Advisors LLC lifted its stake in Inspire Medical Systems by 52.0% in the fourth quarter. Concurrent Investment Advisors LLC now owns 4,815 shares of the company’s stock valued at $444,000 after purchasing an additional 1,647 shares during the last quarter. M&T Bank Corp bought a new position in shares of Inspire Medical Systems during the 4th quarter worth $85,871,000. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Inspire Medical Systems by 990.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 38,404 shares of the company’s stock worth $3,542,000 after purchasing an additional 34,881 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Inspire Medical Systems by 5.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,265 shares of the company’s stock valued at $855,000 after purchasing an additional 507 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INSP shares. Truist Financial cut their price target on Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a report on Tuesday. Morgan Stanley set a $60.00 price objective on shares of Inspire Medical Systems in a report on Wednesday, February 18th. Piper Sandler lowered Inspire Medical Systems from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $85.00 to $55.00 in a research note on Tuesday. Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 14th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Inspire Medical Systems in a research note on Thursday. Four equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Inspire Medical Systems has a consensus rating of “Hold” and a consensus target price of $85.00.

Inspire Medical Systems Stock Down 0.5%

NYSE:INSP opened at $45.48 on Friday. The firm has a market capitalization of $1.31 billion, a P/E ratio of 10.13, a P/E/G ratio of 4.73 and a beta of 0.83. The company has a fifty day moving average of $56.01 and a 200 day moving average of $78.97. Inspire Medical Systems, Inc. has a 52 week low of $44.41 and a 52 week high of $161.88.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. During the same quarter last year, the firm earned $0.10 EPS. The company’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, analysts anticipate that Inspire Medical Systems, Inc. will post 0.91 EPS for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.